首页> 外文期刊>Biopharmaceutics and Drug Disposition >Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition.
【24h】

Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition.

机译:半胱氨酸对蛋白质营养不良大鼠静脉内氯唑沙宗的药代动力学的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of cysteine on the pharmacokinetics of chlorzoxazone (CZX) and one of its metabolites, 6-hydroxychlorzoxazone (OH-CZX), were investigated after intravenous administration of CZX, 25 mg/kg, to control rats (4-week fed on 23% casein diet) and rats with PCM (4-week fed on 5% casein diet) and PCMC (PCM with oral cysteine supplementation, 250 mg/kg, twice daily during the fourth week). In rats with PCM, the area under the plasma concentration-time curve from time zero to time infinity (AUC) of OH-CZX (436 compared with 972 microgmin/ml) and the percentages of intravenous dose of CZX excreted in 8-h urine as OH-CZX (20.2 compared with 38.5%) were significantly smaller than those in control rats. The above data indicated that the formation of OH-CZX from CZX decreased significantly in rats with PCM due to a significant decrease in chlorzoxazone-6-hydroxylase activity (328 compared with 895 pmol/min/mg protein) in the rats. The results were expected since in rats with PCM, hepatic CYP2E1 expression and its mRNA levels decreased significantly as compared to control, and CZX was metabolized to OH-CZX primarily by CYP2E1 in rats. By cysteine supplementation (rats with PCMC), some pharmacokinetic parameters restored fully (hepatic microsomal chlorzoxazone 6-hydroxylation activity based on both mg protein and nmol CYP450) or partially (total body clearance and apparent volume of distribution at steady state of CZX, and AUC, terminal half-life and 8-h urinary excretion of OH-CZX) to control levels.
机译:在将25 mg / kg的CZX静脉内给药于对照大鼠后,研究了半胱氨酸对氯唑沙宗(CZX)及其代谢产物之一的6-羟基氯唑沙宗(OH-CZX)的药代动力学的影响(4周喂食23周) %酪蛋白饮食)和PCM(5%酪蛋白饮食喂养4周)和PCMC(PCM口服半胱氨酸补充剂,250 mg / kg,在第四周每天两次)的大鼠。在患有PCM的大鼠中,OH-CZX从零时到无限时(AUC)的血浆浓度-时间曲线下的面积(436比972 microgmin / ml)和在8小时尿液中排出的CZX静脉内剂量的百分比因为OH-CZX(20.2比38.5%)显着小于对照组大鼠。以上数据表明,由于PCM中的chlorzoxazone-6-羟化酶活性显着降低(328与895 pmol / min / mg蛋白相比,CZX在PCM大鼠中)从OH-CZX的形成显着减少。该结果是可预期的,因为在患有PCM的大鼠中,肝脏CYP2E1的表达及其mRNA水平与对照组相比明显降低,并且CZX在大鼠中主要被CYP2E1代谢为OH-CZX。通过补充半胱氨酸(具有PCMC的大鼠),一些药代动力学参数可以完全恢复(基于mg蛋白和nmol CYP450的肝微粒体氯唑沙宗6-羟基化活性)或部分恢复(在CZX和AUC稳态时的总体清除率和表观分布量) ,终末半衰期和OH-CZX的8小时尿液排泄)来控制水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号